Related Experiment Video
Updated: May 20, 2025
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
ORCHESTRA Delphi consensus: diagnostic and therapeutic management of SARS-CoV-2 infection in haematological patients
Lorenzo Maria Canziani1, Anna Maria Azzini1, Jon Salmanton-García2
1Division of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Insights
COVID-19 presents a high risk for patients with haematological malignancies (HM). Expert consensus was reached on 15 key management strategies for these vulnerable patients.
Area of Science:
- Hematology
- Infectious Diseases
- Public Health
Background:
- Individuals with haematological malignancies (HM) face severe risks from COVID-19 due to compromised immunity.
- Existing clinical guidelines inadequately address COVID-19 management in HM patients, causing inconsistent care.
- There is a critical need for evidence-based recommendations for this high-risk group.
Purpose of the Study:
- To establish expert consensus on managing COVID-19 in patients with haematological malignancies.
- To address key areas including risk stratification, diagnosis, and treatment strategies.
- To provide guidance for clinical practice and fill gaps in current literature.
Main Methods:
- A 28-item Delphi survey was utilized to collect expert opinions.
- Twenty-one experts in haematology and infectious diseases participated.
- The survey focused on critical aspects of COVID-19 care for HM patients.
Main Results:
- Consensus was achieved on 15 out of 28 statements presented to the experts.
- The results highlight areas of agreement among specialists in managing COVID-19 in HM.
Conclusions:
- The Delphi consensus statements offer practical guidance for clinical decision-making.
- These findings aim to improve patient care and standardize treatment for HM patients with COVID-19.
- The consensus provides actionable insights to enhance management protocols for this vulnerable population.
Objectives:
COVID-19 poses a significant risk to individuals with haematological malignancies (HM), as they are particularly vulnerable to severe disease progression and hospitalization due to their compromised immune systems. Many clinical decisions regarding the management of COVID-19 in these patients are yet to be fully addressed by existing guidelines, leading to variability in care.
Methods:
A 28-item Delphi survey was developed to gather expert opinions on key areas of COVID-19 management in patients with HM, including risk stratification for severe COVID-19, diagnostic processes, and treatment decisions.
Results:
Twenty-one experts with backgrounds in haematology and infectious diseases were enrolled. Of the 28 questions posed to the experts, consensus was reached on 15 statements.
Discussion:
These Delphi consensus statements offer valuable suggestions with direct implications for clinical practice, addressing critical areas such as risk identification, appropriate diagnostic approaches, and tailored treatment strategies for patients with HM with COVID-19. The findings provide actionable insights that may help fill gaps in current scientific literature, enhancing patient care and decision-making in this high-risk population.
More Related Videos
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:28Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations: